Physician profile
Robert E Price
NPI 1922093988
$3,053.09
in general payments reported to CMS, 2019-2025
19 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $247 · 2021: $378 · 2022: $367 · 2023: $349 · 2024: $593 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.21 | 2022-2025 | |
| Allergan, INC. | $464.65 | 2019-2022 | |
| Alcon Vision LLC | $274.79 | 2022-2025 | Rocklatan, Tryptyr |
| Sight Sciences, INC. | $237.57 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $227.28 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $150.62 | 2019-2021 | |
| Rxsight INC | $136.93 | 2022-2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $128.51 | 2023-2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $124.13 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $116.77 | 2023-2025 | Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $71.78 | 2019-2024 | Cequa |
| Mallinckrodt Hospital Products INC. | $47.71 | 2022-2024 | Acthar |
| Ivantis, INC | $47.38 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $39.83 | 2022-2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Dompe US, INC. | $33.78 | 2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $26.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.94 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kala Pharmaceuticals, INC. | $18.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.